<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240111060683N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-12</date_registration>
      <primary_sponsor>Gonabad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of an additional dose of vitamin D3 supplementation on the rate of cessation and recurrence of preterm labor in women referred to the hospital</public_title>
      <acronym></acronym>
      <scientific_title>The effect of an additional dose of vitamin D3 supplementation on the rate of cessation and recurrence of preterm labor in women referred to the hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-02-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74998</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Other, Purpose: Prevention, Randomization description: Sampling will be non-random (available) and for random allocation of samples to each of the 2 intervention and control groups, blocks of 4 variables will be used. In this way, first 6 possible states of blocks (BAAB, ABBA, BABA, BBAA, ABAB, AABB) are listed and a number from 1 to 6 is assigned to each block. Then, a number between 1 and 6 is randomly selected and then people are assigned to the vitamin D (B) supplement group and the control group (A) based on the block corresponding to the selected number. This work continues until the sample volume is completed, Blinding description: Blinding in this study is the person who conducts the vitamin D level test, because she does not know which group she is conducting the test.</study_design>
      <phase>3</phase>
      <hc_freetext>The effect of an additional dose of vitamin D3 supplement on the rate of cessation and recurrence of premature labor in women referred to Bahlul Gonabad and Vali Asrbirjand hospitals 1402.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group, an additional dose of 1000 units of vitamin D (2000 units in total) will be prescribed to the intervention group for a maximum of one week after the onset of premature labor symptoms and hospitalization of the mother. It should be noted that the usual dose of 1000 units of vitamin D is prescribed until the end of The pregnancy period will continue. Vitamin D consumption substance, its chemical composition is vitamin D3 (calciferol bag), mothers consume 1000 units of vitamin D3 for one week. And its manufacturing plant in Iran is the holder of the manufacturing license of Hakiman Teb Kar Company. Intervention 2: Control group: The usual dose of 1000 units of vitamin D per day will be prescribed until the end of pregnancy.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I haven't made a decision yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Somayeh Khajeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Motahari 9, Plak 7</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>971966471</zip>
        <telephone>+98 915 562 4250</telephone>
        <email>smyhkhwajh@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Somayeh Khajeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Motahari, Motahari 9 plate 7</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9719664971</zip>
        <telephone>+98 915 562 4250</telephone>
        <email>smyhkhwajh@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Vitamin D serum level less than 32 ng
Willingness to participate in the study
Age range 10-54 years
Gestation age 24 to 36 weeks and 6 days
Not having pregnancy complications based on the mother's statement or information in the mother's file (multiple twins, polyhydramnios, preeclampsia, uncontrolled diabetes, uncontrolled hypothyroidism) that causes premature birth.
No rupture of the water bag
Dilatation of less than 3 centimeters and defecation
Failure to perform cerclage and history of cerclage
Absence of urinary infection and vaginal infection during pregnancy based on the mother's statement or the information in the mother's file</inclusion_criteria>
      <agemin>10 years</agemin>
      <agemax>56 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>The mother's unwillingness to cooperate to take a blood sample
Mother's unwillingness to continue studying
Occurrence of intrauterine fetal death</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O60</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Preterm labor</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group, an additional dose of 1000 units of vitamin D (2000 units in total) will be prescribed to the intervention group for a maximum of one week after the onset of premature labor symptoms and hospitalization of the mother. It should be noted that the usual dose of 1000 units of vitamin D is prescribed until the end of The pregnancy period will continue. Vitamin D consumption substance, its chemical composition is vitamin D3 (calciferol bag), mothers consume 1000 units of vitamin D3 for one week. And its manufacturing plant in Iran is the holder of the manufacturing license of Hakiman Teb Kar Company</i_keyword>
      <i_keyword>Control group: The usual dose of 1000 units of vitamin D per day will be prescribed until the end of pregnancy</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The number of people who gave birth prematurely (before 37 weeks of pregnancy). Timepoint: Before the intervention and one week after the intervention. Method of measurement: Follow-up of mothers and that their delivery was in several weeks of pregnancy.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gonabad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-01-07</approval_date>
        <contact_name>کمیته اخلاق دانشگاه علوم پزشکی گناباد</contact_name>
        <contact_address>Motahari, Motahari 9 Birjand South Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
